Answers are grounded in this paper and cite their sources.
Commentary highlights MHC-I restoration strategies to enhance immune response in CNS cancers, suggesting therapeutic approaches.
Loss or downregulation of MHC-I is a frequent mechanism of immune evasion in central nervous system (CNS) cancers, partially driven by an immunologically cold microenvironment. In this short commentary, we issue a call to action for exploring therapeutic strategies of MHC-I expression restoration in brain cancers to improve patient outcomes. We discuss several potential strategies, including targeting the immunosuppressive microenvironment, epigenetic modulation, and gene therapy approaches. We argue that effective MHC-I restoration may require a combinatorial approach that simultaneously boosts both antigen processing and presentation and remodels the tumor microenvironment. Overcoming CNS-specific barriers, such as the blood-brain barrier, is critical for success. We propose that combining MHC-I re-expression with immunotherapy, chemotherapy, and radiotherapy could provide new therapeutic windows for CNS malignancies.
No takes yet. Share an insight, caveat, or question.
Amikishiev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: